Amgen's Q4 tops views, but 2023 guidance falls on lower end of expectations [MarketWatch]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: MarketWatch
Amgen AMGN, said it earned $1.6 billion, or $3 a share, in the fourth quarter, compared with $1.89 billion, or $3.26 a share, in the year-ago period. Adjusted for one-time items, Amgen earned $4.40 a share. Revenue was flat at $6.8 billion, Amgen said. Analysts polled by FactSet expected the drug maker to report adjusted earnings of $4.10 a share on sales of $6.74 billion. Quarterly sales benefited from a 4% increase in product sales, the company said. Several of its drugs saw “double-digit” volume growth, Amgen said. “We executed effectively in 2022, delivering strong volume growth, advancing numerous first-in-class medicines in our pipeline, and staying on track to achieve our long-term growth objectives,” Chief Executive Robert A. Bradway said. Amgen said its drug Amjevita, a biosimilar in direct competition with AbbVie Inc.'s ABBV, anti-inflamatory drug Humira, is on track. A study to support the drug's interchangeability designation in the U.S. is ongoing, with a data
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Global Colorectal Cancer Drugs Market to Reach USD 12.79 Billion by 2028 with Notable CAGR of 4.57% [Yahoo! Finance]Yahoo! Finance
- Global Antibody Therapeutic Industry Research 2023-2024 & 2033: Exploring the Expanding Role in Managing Cancer, Autoimmune Disorders, and Infectious Diseases [Yahoo! Finance]Yahoo! Finance
- Global MRSA Drugs Market Research Report 2023-2032 Featuring AbbVie, Basilea Pharmaceutica, Crystal Genomics, Cumberland Pharmaceuticals, Melinta Therapeutics, Paratek Pharmaceuticals, and Pfizer [Yahoo! Finance]Yahoo! Finance
- Global Highly Potent API (Active Pharmaceutical Ingredient) Industry Research 2023-2033: Advancements in Containment Technologies, and Increasing Investment for Manufacturing Units [Yahoo! Finance]Yahoo! Finance
- AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Barclays PLC from $185.00 to $195.00. They now have an "overweight" rating on the stock.MarketBeat
ABBV
Earnings
- 2/2/24 - Beat
ABBV
Sec Filings
- 3/26/24 - Form PX14A6G
- 3/22/24 - Form 4
- 3/21/24 - Form 144/A
- ABBV's page on the SEC website